Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9066
Abstract: 9066 Background: Taletrectinib (AB-106; DS-6051b) is a potent, selective ROS1/NTRK inhibitor. In two phase I trials, NSCLC patients (pts) with ROS1 fusion who received taletrectinib as first line ROS1 TKI had an objective response rate…
read more here.
Keywords:
fusion;
nsclc patients;
cell;
ros1 fusion ... See more keywords